Question 1

What specific information will be collected during this follow-up study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65) clinical trial (NCT02946879). Contact the study team or your healthcare provider for specific answers.

Question 2

How will this study help improve understanding of the treatment's long-term effects?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65) clinical trial (NCT02946879). Contact the study team or your healthcare provider for specific answers.

Question 3

Are there any risks associated with participating in this follow-up study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65) clinical trial (NCT02946879). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for visits, and what will those visits involve?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65) clinical trial (NCT02946879). Contact the study team or your healthcare provider for specific answers.

Question 5

What should I expect in terms of monitoring my eye health during this study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65) clinical trial (NCT02946879). Contact the study team or your healthcare provider for specific answers.

Question 6

Will there be any additional treatments or interventions during this follow-up?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65) clinical trial (NCT02946879). Contact the study team or your healthcare provider for specific answers.

Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)

What this study is about

Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)

What this study is about